The short answer
Have CBD reviewed before taking it with alprazolam. Prescription cannabidiol can cause sedation, and other sedating medicines can increase that effect.
What this answer covers
Oral cannabidiol, with strongest safety information from prescription purified CBD; not every consumer concentration, route or THC-containing product.
- Supplement or preparation
- Cannabidiol
- Medication ingredient
- alprazolam
Why a review is appropriate
Prescription cannabidiol labeling recognizes somnolence and sedation, potentially increased by other CNS depressants. Alprazolam itself can impair alertness, so the actual combination deserves review.
The comparison study was not co-use
In a study of recreational polydrug users, purified CBD was compared with alprazolam and other treatments given separately. Less impairment with CBD alone does not prove CBD plus alprazolam is safe.
Bring the exact CBD product
List the daily amount, route, other ingredients and any THC content. There is no validated dosing gap that removes possible combined impairment, and prescription CBD is not interchangeable with every retail product.
Protect your alertness
Alprazolam can impair coordination and alertness. Avoid driving when affected. Seek urgent help for severe difficulty waking or breathing, and tell the prescriber about all other sedating medicines and alcohol.
Evidence and practical considerations
Side effects & toxicity
Conditional combined-alertness caution is supported by exact drug labels; no exact clinical risk estimate or automatic CYP prediction.
- Exact scope
- Oral cannabidiol, with strongest safety information from prescription purified CBD; not every consumer concentration, route or THC-containing product. with Exact oral alprazolam; no blanket benzodiazepine metabolic or route transfer.
- Medication form and route
- oral; other cannabis routes only if explicitly discussed
- Timing or duration
- Exact duration and dose depend on source; single-dose and chronic use are distinguished.
What remains uncertain
- CBD study used alprazolam as an alternative comparator, not simultaneous treatment. Prescription epilepsy-product risks cannot be assigned quantitatively to all CBD products.
Factors that may matter: preparation and plant part; dose; other medicines; baseline alertness; clinical indication.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral alprazolam.
CNS depression, impaired coordination and alertness can occur; concomitant CNS depressants require caution. Dependence and withdrawal risks require individualized tapering rather than abrupt cessation. Metabolism involves CYP3A; inhibitors and inducers may alter exposure. Not the same metabolic pathway profile as oxazepam or temazepam.
How this applies: Exact RxNorm ingredient and oral formulation confirmed in original label; use exact indication and metabolic boundaries.
Does not quantify the requested botanical interaction risks, prove every herb is sedating, or establish a protective supplement interval.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving prescription purified cannabidiol oral solution.
Somnolence and sedation occur and can be potentiated by other CNS depressants. Cannabidiol is a weak CYP1A2 inhibitor; some substrate exposures may increase.
How this applies: Supports a conditional combined-sleepiness precaution with a medicine independently known to cause somnolence; not a numerical pair-risk estimate.
No alprazolam study and no equivalence to every nonprescription CBD product, concentration or route. Epilepsy trials had other medicines, especially clobazam, affecting sedation.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy recreational polydrug users; 43 entered treatment/safety assessment.
CBD showed less abuse-related response and no observable cognitive/psychomotor effect compared with alprazolam in this experiment.
How this applies: Apply only to exact medication, preparation and study exposure; comparator treatment is not co-use.
Separate comparator arms, not CBD plus alprazolam; cannot establish combination safety or generalize to consumer CBD products.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact claims adjudicated against captured originals and explicit comparator/co-use boundaries. | |
| Research summary published |
Article revision: ea3bd6056b8de7a7
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.